Liu et al. (98) reported variation of granulocytic MDSCs (CD33+ CD11b+ CD14− CD15+) in advanced NSCLC patients treated with chemotherapy; nonprogressors (partial response or stable disease, n = 41) decreased their Gr-MDSC frequency compared to baseline (p < 0.0001), contrary to progressors (n = 37), who kept similar frequency. This evidence concerns the gene FUT4 and non-small cell lung carcinoma.